- ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option<figure><div><img src="https://imgproxy.divecdn.com/s1OP69WlFaq8Ze7MFeyEVPnIDEywrEml5dBx5ZtKpus/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNjY1Nzc4NTU4XzEua…BioPharma Dive · 1mo ago↗ source
- J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS fieldJohnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a preclinical startup working on degrader antibody conjugates. J&J no…Endpoints · 1mo ago↗ source
- GSK inks multi-target pact with Engitix; Sangamo considers strategic optionsPlus news about Pfizer's latest label expansion. 🤝 GSK inks multi-target liver pact with Engitix: London-based Engitix will use disease models based on its extracellular matrix technology to ide…